<DOC>
	<DOCNO>NCT01752517</DOCNO>
	<brief_summary>Although fist-line therapy Cisplatin etoposide ( EP ) Carboplatin etoposide ( CE ) second-line therapy topotecan give , patient ED-SCLC still relapse 2-year survival le 10 % . There standard treatment recommendation group patient fail second-line therapy good performance status . Some cytotoxic drug treatment non-small cell lung cancer , i.e . vinorelbine , paclitaxel , ifosfamide , use refractory recurrent SCLC patient . Recently , retrospective study show overall response rate 30 % , median progression free survival ( PFS ) 6.5 month , median overall survival 10.4 month advance combined SCLC patient treat first-line regimen vinorelbine , ifosfamide cisplatin ( NIP ) . Because previous platinum administration patient 's performance status , vinorelbine ifosfamide ( NI ) combine use third-line therapy refractor recurrent ED-SCLC lung cancer center . And clinical trial design prospectively investigate efficacy safety NI regimen refractory recurrent ED-SCLC patient center .</brief_summary>
	<brief_title>Vinorelbine Ifosfamide Third-line Treatment Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>Small cell lung cancer ( SCLC ) highly aggressive disease characterize rapid doubling time , high growth fraction , early development disseminate disease , dramatic response first-line chemotherapy radiation . Small cell lung cancer account approximately 20 % -25 % lung cancer patient . SCLC patient categorize limited disease , define disease confine ipsilateral hemithorax encompass within tolerable radiation port , extensive disease ( ED ) , define presence overt metastatic disease determine image physical examination . Two third patient diagnose ED presentation . Despite development novel cytotoxic drug , therapeutic approach SCLC stagnant twenty year . Standard treatment ED-SCLC remain EP CE , regimen yield median survival approximately 9 month 5-year survival le 1 % . Most patient destine relapse , prognosis group patient relapse poor . Patients relapse &lt; 3 month first-line therapy commonly call refractory , patient relapse 3 month therapy label sensitive . In randomized multicenter study , von Pawel et al compare cyclophosphamide , adriamycin , vincristine ( CAV ) topotecan single agent patient relapse least 60 day ( 2 month ) initial therapy . The response rate 24.3 % patient treat topotecan 18.3 % patient treat CAV ( P=0.285 ) . Median time progression 13.3 week topotecan arm 12.3 week CAV arm . Median survival time 25 week topotecan 24.7 week CAV . The proportion patient symptom improvement great topotecan arm CAV arm . The author conclude topotecan least effective CAV treatment patient recurrent SCLC . So guideline SCLC , topotecan recommended standard second-line treatment patient relapse less 3 month . As patient relapse six month end initial treatment , EP CE regimen recommend use .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>histologically cytologically confirm EDSCLC ; age &gt; 18 &lt; 75 ; measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) ; previous treatment include firstline therapy EP CE secondline therapy topotecan ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 ; life expectancy &gt; 3 month ; neutrophil count &gt; 1500/ul ; platelet count &gt; 100,000ul ; hemoglobin level &gt; 9g/dl ; bilirubin level &lt; 1.5mg/dL ; creatinine level &lt; 2mg/dl ; alanine transaminase ( AST ) level &lt; 2.5× upper limit normal ( ULN ) ( &lt; 5× ULN liver metastasis present ) ; previous anticancer therapy include vinorelbine ifosfamide ; newly diagnose central nervous system ( CNS ) metastasis treat radiotherapy surgery ; additional malignancy ; uncontrolled systemic disease ; pregnancy breast feeding phase ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>ifosfamide</keyword>
	<keyword>third-line treatment</keyword>
</DOC>